Clin Mol Hepatol.
2022 Oct;28(4):935-938. 10.3350/cmh.2022.0175.
Personalized medicine in nonalcoholic fatty liver disease
- Pirola CJ
1,2 - Sookoian S1,3
- Affiliations
-
- 1Institute of Medical Research A Lanari, School of Medicine, University of Buenos Aires, Ciudad Autónoma de Buenos Aires, Argentina
- 2Department of Molecular Genetics and Biology of Complex Diseases, National Scientific and Technical Research Council (CONICET)-University of Buenos Aires, Institute of Medical Research (IDIM), Ciudad Autónoma de Buenos Aires, Argentina
- 3Department of Clinical and Molecular Hepatology, National Scientific and Technical Research Council (CONICET)-University of Buenos Aires, Institute of Medical Research (IDIM), Ciudad Autónoma de Buenos Aires, Argentina
- KMID: 2534359
- DOI: http://doi.org/10.3350/cmh.2022.0175
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
- Nonalcoholic fatty liver disease: pathogenesis and treatment
- Elevated serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease
- The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence?
- Clinical Predictors Reflecting the Pathologic Severity of Nonalcoholic Steatohepatitis in Patients with Nonalcoholic Fatty Liver
